JP2010519904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519904A5 JP2010519904A5 JP2009551830A JP2009551830A JP2010519904A5 JP 2010519904 A5 JP2010519904 A5 JP 2010519904A5 JP 2009551830 A JP2009551830 A JP 2009551830A JP 2009551830 A JP2009551830 A JP 2009551830A JP 2010519904 A5 JP2010519904 A5 JP 2010519904A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- seq
- cancer
- valine
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 82
- 229920001184 polypeptide Polymers 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 51
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 42
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 42
- 239000004474 valine Substances 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 29
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 29
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 24
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 23
- 239000004473 Threonine Substances 0.000 claims description 23
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 19
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 19
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 19
- 229960000310 isoleucine Drugs 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 229940024606 amino acid Drugs 0.000 claims description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 13
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 11
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 10
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 10
- 102100037850 Interferon gamma Human genes 0.000 claims description 10
- 108010074328 Interferon-gamma Proteins 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 10
- 102000000588 Interleukin-2 Human genes 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
- 206010057644 Testis cancer Diseases 0.000 claims description 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 241000700618 Vaccinia virus Species 0.000 claims description 6
- 230000005907 cancer growth Effects 0.000 claims description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 201000002314 small intestine cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- 241000710929 Alphavirus Species 0.000 claims description 5
- 108010084313 CD58 Antigens Proteins 0.000 claims description 5
- 241000991587 Enterovirus C Species 0.000 claims description 5
- 208000000666 Fowlpox Diseases 0.000 claims description 5
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 5
- 241000710960 Sindbis virus Species 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 5
- -1 tryptophan Amino acid Chemical class 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 241000701447 unidentified baculovirus Species 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 230000005867 T cell response Effects 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 7
- 102000001327 Chemokine CCL5 Human genes 0.000 description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000025189 neoplasm of testis Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 208000014680 small intestine neoplasm Diseases 0.000 description 2
- 208000025421 tumor of uterus Diseases 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000006385 lung benign neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90423607P | 2007-02-28 | 2007-02-28 | |
| US60/904,236 | 2007-02-28 | ||
| PCT/US2008/055185 WO2008106551A2 (en) | 2007-02-28 | 2008-02-27 | Brachyury polypeptides and methods for use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014083444A Division JP5767733B2 (ja) | 2007-02-28 | 2014-04-15 | ブラキュリポリペプチドおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519904A JP2010519904A (ja) | 2010-06-10 |
| JP2010519904A5 true JP2010519904A5 (https=) | 2011-04-07 |
| JP5596980B2 JP5596980B2 (ja) | 2014-10-01 |
Family
ID=39650527
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551830A Active JP5596980B2 (ja) | 2007-02-28 | 2008-02-27 | ブラキュリポリペプチドおよび使用方法 |
| JP2014083444A Active JP5767733B2 (ja) | 2007-02-28 | 2014-04-15 | ブラキュリポリペプチドおよび使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014083444A Active JP5767733B2 (ja) | 2007-02-28 | 2014-04-15 | ブラキュリポリペプチドおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8188214B2 (https=) |
| EP (3) | EP2125868B1 (https=) |
| JP (2) | JP5596980B2 (https=) |
| AU (1) | AU2008221383B2 (https=) |
| CA (1) | CA2678404C (https=) |
| DK (1) | DK2918598T3 (https=) |
| WO (1) | WO2008106551A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2819552C (en) | 2010-12-09 | 2023-09-26 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
| MX350661B (es) * | 2011-03-17 | 2017-09-13 | Us Health | Composiciones inmunoterapeuticas de levadura-brachyuri. |
| WO2014043535A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014043518A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| AU2014265873B2 (en) | 2013-03-19 | 2019-01-17 | Globeimmune, Inc. | Yeast-based immunotherapy for chordoma |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| ES2901468T3 (es) * | 2015-07-31 | 2022-03-22 | Bavarian Nordic As | Promotores para mejorar la expresión en poxvirus |
| AU2016303525B2 (en) | 2015-08-03 | 2021-01-21 | Globeimmune, Inc. | Modified yeast-Brachyury immunotherapeutic compositions |
| EP4137150A1 (en) | 2015-08-03 | 2023-02-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
| US20190183870A1 (en) | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| EP3463450A4 (en) * | 2016-06-03 | 2020-07-29 | Etubics Corporation | COMPOSITIONS AND METHODS OF ANTI-TUMOR VACCINATION USING ANTIGENS ASSOCIATED WITH PROSTATE CANCER |
| CA3026345A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu |
| AU2018266103B2 (en) | 2017-05-09 | 2024-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
| US11170872B2 (en) | 2019-11-05 | 2021-11-09 | Apeel Technology, Inc. | Prediction of latent infection in plant products |
| WO2022187963A1 (en) * | 2021-03-10 | 2022-09-15 | Provincial Health Services Authority | Immunotherapy agents targeting brachyury and methods of using same |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4444487A (en) | 1979-07-02 | 1984-04-24 | Xerox Corporation | Multiple-flash fuser |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
| US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| CA1340456C (en) | 1986-07-07 | 1999-03-23 | Hubert J.P. Schoemaker | Chimeric rodent/human immunoglobulins specific for tumor-associated antigens |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AP56A (en) | 1987-01-30 | 1989-09-26 | Smithkline Biologicals S A | Hepatitis B virus surface antigens and hybrid antigehs containing them. |
| DE3789866T2 (de) | 1987-07-17 | 1994-09-22 | Rhein Biotech Gesellschaft Fuer Neue Biotechnologische Prozesse Und Produkte Mbh, 40595 Duesseldorf | DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung. |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| DE10399032I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| CA1340203C (en) | 1987-09-16 | 1998-12-15 | Noboru Yanagida | Recombinant apivoxvirus |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| US5543508A (en) | 1987-12-15 | 1996-08-06 | Gene Shears Pty. Limited | Ribozymes |
| ATE138106T1 (de) | 1988-07-20 | 1996-06-15 | David Segev | Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen |
| US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| GB9007024D0 (en) | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| WO1991019803A1 (en) | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
| RO116459B1 (ro) | 1991-07-25 | 2001-02-28 | Idec Pharma Corp | Compozitie imunogena |
| US5709860A (en) | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| DE69311538D1 (de) | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| ES2168380T3 (es) | 1994-07-15 | 2002-06-16 | Organon Teknika Bv | Utilizacion de arn polimerasa para mejorar un procedimiento de amplificacion de acido nucleico. |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| WO1996025538A1 (en) | 1995-02-14 | 1996-08-22 | Chisso Corporation | Biodegradable fiber and nonwoven fabric |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| AT402203B (de) | 1995-06-13 | 1997-03-25 | Himmler Gottfried Dipl Ing Dr | Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren |
| US6165460A (en) | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| GB0023203D0 (en) * | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| WO1999004819A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| WO1999029864A1 (en) * | 1997-12-09 | 1999-06-17 | Virogenetics Corporation | Recombinant vaccinia constructs expressing feline il-2, compositions and methods of use thereof |
| CA2315256A1 (en) | 1997-12-16 | 1999-06-24 | Valentis, Inc. | Needle-free injection of formulated nucleic acid molecules |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6849255B2 (en) * | 1998-08-18 | 2005-02-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for enhancing cartilage repair |
| CA2341642C (en) | 1998-09-01 | 2011-05-24 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor |
| AR021849A1 (es) * | 1998-09-30 | 2002-08-07 | Corixa Corp | Composiciones y metodos para la inmunoterapia especifica de wt1 |
| US20020131976A1 (en) | 1998-12-23 | 2002-09-19 | Ajit Lalvani | Tuberculosis vaccine |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| AU781925B2 (en) | 1999-07-13 | 2005-06-23 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | T-cell receptor gamma alternate reading frame protein, (TARP) and uses thereof |
| CA2383213A1 (en) | 1999-09-10 | 2001-03-15 | Fordham University | Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins |
| US7094408B2 (en) * | 2000-04-28 | 2006-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Immunogenicity using a combination of DNA and vaccinia virus vector vaccines |
| WO2002078516A2 (en) * | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| AU2002330714A1 (en) | 2001-05-30 | 2003-01-02 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
| EP1513934B1 (en) * | 2002-06-06 | 2011-03-02 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human colon cancers |
| AU2003295328A1 (en) * | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2006004182A1 (ja) * | 2004-07-07 | 2006-01-12 | Nec Corporation | 配列予測システム |
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
-
2008
- 2008-02-27 WO PCT/US2008/055185 patent/WO2008106551A2/en not_active Ceased
- 2008-02-27 EP EP08743578.0A patent/EP2125868B1/en active Active
- 2008-02-27 AU AU2008221383A patent/AU2008221383B2/en active Active
- 2008-02-27 CA CA2678404A patent/CA2678404C/en active Active
- 2008-02-27 EP EP15162282.6A patent/EP2918598B1/en active Active
- 2008-02-27 DK DK15162282.6T patent/DK2918598T3/en active
- 2008-02-27 US US12/528,796 patent/US8188214B2/en active Active
- 2008-02-27 EP EP11195533A patent/EP2444410A3/en not_active Withdrawn
- 2008-02-27 JP JP2009551830A patent/JP5596980B2/ja active Active
-
2012
- 2012-04-30 US US13/460,587 patent/US8613933B2/en active Active
-
2013
- 2013-12-23 US US14/138,629 patent/US20140135488A1/en not_active Abandoned
-
2014
- 2014-04-15 JP JP2014083444A patent/JP5767733B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519904A5 (https=) | ||
| JP2025160281A (ja) | 個別化ワクチン | |
| US10688164B2 (en) | CMV vectors comprising microRNA recognition elements | |
| JP2007511216A5 (https=) | ||
| WO2018223600A1 (zh) | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 | |
| WO2018223601A1 (zh) | 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体 | |
| Lizée et al. | Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells | |
| KR20160102024A (ko) | 아데노바이러스 및 상응하는 플라스미드의 제조 방법 | |
| JP2014207903A5 (https=) | ||
| CN114729320B (zh) | 用于将细胞重新程序化为能够呈递抗原的树突细胞2型的组合物、方法及其用途 | |
| KR20100021603A (ko) | 신호전달 펩타이드 | |
| JP2005537007A5 (https=) | ||
| Sharma et al. | Polyomavirus BK non‐coding control region rearrangements in health and disease | |
| WO2021150635A1 (en) | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment | |
| CN111971394B (zh) | 嵌合抗原受体的肿瘤环境特异性表达 | |
| KR19990087718A (ko) | 인간 종양 유전자 치료를 위한 재조합 아데노바이러스 벡터 | |
| CN116057067A (zh) | 用于治疗黑素瘤的ctl抗原的融合蛋白 | |
| WO2021239586A1 (en) | Adenovirus for anti-tumour therapy | |
| CN119736337A (zh) | Matv51重组腺病毒载体、应用、制备方法及hpv16/18/52治疗性疫苗 | |
| CN103484462A (zh) | Survivin启动子调控CD基因的重组腺病毒载体构建及其应用 | |
| JP2025514843A (ja) | 核酸構築物及びその使用 | |
| CN109847054B (zh) | TgGRA15在制备诱导I型干扰素的药物中的应用 | |
| RU2768287C1 (ru) | Противоопухолевая композиция | |
| CN114410626A (zh) | 一种新型的消化道肿瘤特异性lgr5核心启动子及其筛选构建方法 | |
| CN1152138C (zh) | 一种腺相关病毒载体及其制备方法和用途 |